Actively Recruiting
Acute Microbial Switch
Led by Maastricht University Medical Center · Updated on 2024-08-22
28
Participants Needed
2
Research Sites
95 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In this project the investigators will test if it is possible to measure changes in intestinal gas production after supplementation of a complex fiber mixture over a 36 hour period in both lean normoglycemic individuals and individuals with insulin resistance and/or prediabetes with overweight when compared with a placebo Changes in intestinal gas production will also be related to energy expenditure, substrate metabolism, microbial composition and related metabolites in feces, blood and urine.
CONDITIONS
Official Title
Acute Microbial Switch
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Lean normoglycemic individuals with BMI between 18.5 and 24.9 kg/m2
- Normal fasting glucose less than 5.6 mmol/L and HOMA-IR below 2.2 for lean group
- Overweight or obesity with BMI between 28 and 40 kg/m2
- Insulin resistance (HOMA-IR above 2.2) and/or impaired fasting glucose (plasma glucose 5.6 mmol/L or higher) for overweight group
- Age between 30 and 75 years
- Normal blood pressure: systolic 100-150 mmHg and diastolic 60-100 mmHg
- Weight stable for at least 3 months with variation within ±2 kg
You will not qualify if you...
- Type 2 diabetes defined as fasting plasma glucose 7.0 mmol/L or higher
- Gastroenterological diseases
- Abdominal surgery affecting the gastrointestinal tract
- Cardiovascular disease, cancer, liver or kidney malfunction, or diseases with life expectancy under five years
- Abuse of alcohol (more than 15 standard units per week), drugs, or excessive nicotine use (more than 20 cigarettes per day)
- Plans to lose weight or following a low-calorie diet
- Regular use of pre- or probiotic supplements within three months before study
- Intensive exercise training over three hours per week
- Use of medications affecting glucose or fat metabolism, including certain lipid-lowering drugs, glucose-lowering agents, anti-inflammatory or immunosuppressive drugs, and antioxidants
- Regular use of laxatives
- Antibiotic use within the last three months
- Vegan diet
- Lactose intolerance
- Pregnancy or breastfeeding for women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Department of Human Biology, Maastricht University Medical Centre
Maastricht, Netherlands, 6200MD
Actively Recruiting
2
Maastricht University Medical Centre
Maastricht, Netherlands
Actively Recruiting
Research Team
G
Gillian Larik, Msc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here